AACR Conference on Frontiers in Basic Cancer Research to be held in San Francisco

What: For more than 100 years, the American Association for Cancer Research has been the premier leader in the basic science of cancer research.

This year, Elizabeth H. Blackburn, Ph.D., the immediate past president of the AACR and a recent Nobel laureate, will chair the Second AACR Conference on Frontiers in Basic Cancer Research. This conference will unite cancer research leaders from across the globe to encourage and strengthen collaborative research efforts.

The Second AACR Conference on Frontiers in Basic Cancer Research is a unique opportunity for science writers, editors and reporters to gain cutting-edge insight about the field of basic cancer research.

Featured speakers and their topics include:

  • Bert Vogelstein, M.D., Sidney Kimmel Cancer Center at Johns Hopkins, "Cancer Genomes and Their Implications for Research";
  • Zena Werb, Ph.D., University of California, San Francisco, "New Insights Into the Microenvironment and Metastasis";
  • Jeremy Rich, M.D., The Cleveland Clinic, "The Complexity of Tumor Cell Hierarchies";
  • Alan Ashworth, Ph.D., Institute of Cancer Research, London, "Harnessing Genetic Dependencies in Cancer Therapy"; and
  • Jeffrey Engleman, M.D., Ph.D., Massachusetts General Hospital, "Overcoming Intrinsic and Acquired Resistance to Targeted Therapies."

When: Sept. 14-18, 2011

Where: InterContinental San Francisco Hotel
San Francisco, Calif.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients